ClinicalTrials.gg
Active, not recruitingNCT01849510SPIN-METUpdated Oct 27, 2026

Efficacy of Dose Intensified Radiotherapy of Spinal Metastases by Hypofractionated Radiation and IGRT hfSRT Mediated Boost

A Phase 2 interventional study of hypofractionated 12x3 Gy + integrated boost 12x4 Gy and hypofractionated 10x3 Gy in Spinal Metastases, sponsored by University of Erlangen-Nürnberg Medical School. Active, not recruiting at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by University of Erlangen-Nürnberg Medical School · Phase 2, Interventional, and Treatment

How we know

Updated Oct 27, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 323 studies in Neoplasm Metastasis with a site in Germany — 52 open to participants now, 91 under way, 36 of them phase 3. Neoplasm Metastasis · Germany.

Planned enrollment
174th of 292
155 · median 214
Started
2013
with 14 others
Phase 2
81 of 323
7 open now
Primary completion
2028-04
later than 61 of 90 live
Registered
131st of 323
by date

Among the 323 studies in Neoplasm Metastasis with a site in Germany, this one is the 174th largest by planned enrollment of the 292 interventional ones that give a count, is one of 15 that started in 2013, is one of 81 in phase 2, reaches primary completion later than 61 of the 90 other live ones, and was the 131st registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

52 of the 323 studies in Neoplasm Metastasis with a site in Germany are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 323 studies in Neoplasm Metastasis with a site in Germany, or all of them as a file.
02

Study summary

Spinal metastases indicate for an incurable course of disease. Local tumor control after palliative radiotherapy of spinal metastases (10x3 Gy, 1x8Gy) is between 61 to 81%. In 30% of patients, therapy fails locally within two years associated with further symptoms that are difficult to treat, because a further radiation of already radiated vertebra leads to a higher rate of myelitis. This trial aims to improve local tumor control and control of pain by radiotherapy with increase in total and single dose. Dose elevation is realized by simultaneous, integrated boost mediated by image-guided stereotactic radiotherapy (IGRT \& hfSRT) and by elevation of elective dose in vertebral body with 12x3 Gy (standard: 10x3 Gy). Primary endpoint is local tumor control (time up to progression). Secondary endpoints are pain control associated with quality of live, severity of acute and chronic adverse effects and overall survival. It is planned to recruit a total number of 155 patients.

03

Conditions studied

  • Spinal Metastases

Browse trials for

Keywords

  • spinal metastases
  • vertebral body
  • stereotaxis
  • image-guided radiotherapy
  • hypofractionated
  • dose intensified
  • dose elevation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • minimum age 18
  • expectance of life at least 6 months
  • -Score > 50
  • 1-3 vertebral body
  • Up to 5 other, macroscopic metastases
  • effective
  • geographic reachability of patients
  • Signed study-specific consent form prior to therapy
  • no on-treatment participation on other trials

Exclusion criteria

Exclusion Criteria:

  • initial required neurosurgical decompression
  • rapid, neurological deterioration
  • prior radiotherapy of region for planned radiation
  • conditions that preclude the application of magnetic resonance tomography
  • : multiple myeloma or lymphoma
  • technical conditions preclude stereotactic irradiation (technical limitations of device)
  • pregnant or nursing women
  • Fertile patients who refuse effective during study treatment
  • persistent drug and/or alcohol abuse
  • patients that are not able or willing to behave according to study protocol
  • absent attendance for personal, disease related data storage and transfer
  • on-treatment participation on other trials
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
155 participants (estimated)

Study arms

  • Experimental
    dose intensified

    hypofractionated 12x3 Gy + integrated boost 12x4 Gy

    Radiation: hypofractionated 12x3 Gy + integrated boost 12x4 Gy

  • Active comparator
    standard

    hypofractionated 10x3 Gy

    Radiation: hypofractionated 10x3 Gy

Interventions

  • Radiationhypofractionated 12x3 Gy + integrated boost 12x4 Gy

    hypofractionated, homogeneous radiation (12x3 Gy) with simultaneously administrated, integrated boost (12x4 Gy) mediated by IGRT \& hfSRT

  • Radiationhypofractionated 10x3 Gy

    hypofractionated, homogeneous radiation (10x3 Gy)

06

What researchers measure

Primary outcomes

  1. tumor control (time up to progression)

    Time frame: up to progression (MR-imaging), max. 5 years after therapy

Secondary outcomes

  1. severity of acute and chronic adverse effects

    Time frame: acute: assessment up to 6 weeks after therapy; chronic: assessment up to 60 months after therapy or up to progression

  2. overall survival

    Time frame: assessment 60 months after therapy or up to death

  3. pain control

    by visual analog scala and questionnaires according pain

    Time frame: assessment 60 months after therapy

07

Study locations

3 sites
  • Universitätsklinikum Erlangen
    Erlangen, 91054, Germany
  • Universitätsklinikum Frankfurt; Strahlentherapie
    Frankfurt/M., 60590, Germany
  • Universitätsklinikum Regensburg, Strahlentherapie
    Regensburg, 93053, Germany
08

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Mar 2013, a primary completion of Apr 2028 and a completion of Apr 2029. It does not say whether these dates are actual or estimated.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Apr 2019 → Apr 2028 and completion Apr 2019 → Apr 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2013
First posted
May 8, 2013
Start
Mar 2013
Primary completionEst.
Apr 2028was Apr 2019
CompletionEst.
Apr 2029was Apr 2019
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Active, not recruiting
changed Oct 27, 2026
Primary completion
Apr 2019→Apr 2028
Oct 27, 2026
Study completion
Apr 2019→Apr 2029
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Status unknown→Active, not recruiting
    Primary completion Apr 2019→Apr 2028
    Study completion Apr 2019→Apr 2029
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT01849510
Responsible party
Sponsor
First posted
May 8, 2013
Start date
Mar 2013
Primary completion
Apr 2028 (estimated)
Completion
Apr 2029 (estimated)
Last update
Oct 27, 2026

Study contacts

Sabine Semrau, MD
principal investigator · Strahlenklinik, Universitätsklinikum Erlangen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion